Recently, with the approval of dimethyl fumarate (a compound capable of blocking the interaction between Keap1 and Nrf2) for the treatment of multiple sclerosis, other studies [122] have suggested that the use of certain skin allergens, such as dimethyl fumarate, phthalic anhydride, or methyl heptine carbonate, at safe concentrations could yield promising results in AD by decreasing ROS, inhibiting inflammatory activity, or even by aiding intracellular Ca2+ homeostasis, as it has also been suggested that up-regulation of Ca2+ may be upstream of the mechanisms that produce AD [123]. Here, KEAP1 is linked to Alzheimer disease.